NCT06969352View on ClinicalTrials.gov

A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

Not yet recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions
Gliomas
Interventions
DRUG

Vorasidenib

"Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older:~* For patients weighing at least 40 kg: 40 mg, orally, once daily.~* For patients weighing less than 40 kg: 20 mg, orally, once daily."

Trial Locations (3)

Unknown

Beijing Tiantan Hospital, Capital Medical University, Beijing

West China Lecheng Hospital Sichuan University, Qionghai

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
collaborator

Institut de Recherches Internationales Servier (I.R.I.S.)

INDUSTRY

collaborator

Hainan Boyan Medical Research Co. Ltd.

UNKNOWN

collaborator

Fantastic Bioimaging Co., Ltd.

UNKNOWN

collaborator

Clinical TrialService (Guangzhou) Co.,Ltd

UNKNOWN

lead

Servier (Tianjin) Pharmaceutical Co. LTD.

INDUSTRY